Emyria Ltd (ASX:EMD) MD Michael Winlo talks Proactive through the highlights of its June quarter. The company initiated the acquisition of the Pax Centre, extending its reach in the mental health space. EMD received Human Research Ethics Committee approval to commence EMDMA-001, a novel MDMA-assisted therapy trial for PTSD. Also, at the start of the period, Emyria signed an exclusive licensing and commercialisation term sheet with Aspen Pharmacare (JSE:APN) Australia, securing a major partner to support the registration and commercialisation of the prospective EMD-RX5 treatment for mild anxiety and stress.
Emyria advances development and commercialisation of unique drug products
